About Omeros Corporation
https://www.omeros.comOmeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders.
CEO
Gregory A. Demopulos
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 75
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:4.45M
Value:$58.23M
INGALLS & SNYDER LLC
Shares:4.11M
Value:$53.71M
BLACKROCK INC.
Shares:4.1M
Value:$53.65M
Summary
Showing Top 3 of 166
About Omeros Corporation
https://www.omeros.comOmeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $26.39M ▲ | $-30.92M ▼ | 0% | $-0.47 ▼ | $-15.59M ▲ |
| Q2-2025 | $0 | $22.06M ▼ | $-25.42M ▲ | 0% | $-0.43 ▲ | $-32.15M ▲ |
| Q1-2025 | $0 | $34.97M ▼ | $-33.46M ▼ | 0% | $-0.58 ▼ | $-33.62M ▼ |
| Q4-2024 | $0 | $35.36M ▼ | $-31.36M ▲ | 0% | $-0.54 ▲ | $-33.06M ▼ |
| Q3-2024 | $0 | $35.41M | $-32.23M | 0% | $-0.56 | $-32.82M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $36.09M ▲ | $185.71M ▼ | $406.18M ▼ | $-220.48M ▲ |
| Q2-2025 | $28.74M ▼ | $200.57M ▼ | $429.25M ▼ | $-228.69M ▼ |
| Q1-2025 | $52.41M ▼ | $235.16M ▼ | $448.71M ▼ | $-213.55M ▼ |
| Q4-2024 | $90.13M ▼ | $277.08M ▼ | $459.69M ▼ | $-182.61M ▼ |
| Q3-2024 | $123.16M | $313.33M | $467.51M | $-154.17M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-30.92M ▼ | $-18.47M ▲ | $-6.86M ▼ | $25.82M ▲ | $491K ▲ | $-18.48M ▲ |
| Q2-2025 | $-25.42M ▲ | $-21.94M ▲ | $21.3M ▼ | $-1.72M ▲ | $-2.36M ▼ | $-21.95M ▲ |
| Q1-2025 | $-37.56M ▼ | $-35.84M ▼ | $38.54M ▲ | $-1.84M ▲ | $861K ▼ | $-35.88M ▼ |
| Q4-2024 | $-31.36M ▲ | $-28.98M ▲ | $34.95M ▼ | $-4.09M ▲ | $1.88M ▲ | $-29.01M ▲ |
| Q3-2024 | $-32.23M | $-32.06M | $36.04M | $-4.58M | $-599K | $-32.06M |
CEO
Gregory A. Demopulos
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 75
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:4.45M
Value:$58.23M
INGALLS & SNYDER LLC
Shares:4.11M
Value:$53.71M
BLACKROCK INC.
Shares:4.1M
Value:$53.65M
Summary
Showing Top 3 of 166